Publications by authors named "Andrew J Garton"

Claim this Profile
E
Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders.
Theresa M LaVallee, Diego Alvarado, Andrew J Garton, E Sergio Trombetta, Richard Gedrich

Crit Rev Oncog· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.
Cheryl A London, Heather L Gardner, Sarah Rippy, Gerald Post, Krista La Perle, Andrew J Garton

Clin Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.
Andrew J Garton, Scott Seibel, Lori Lopresti-Morrow, Linda Crew, Neal Janson

Mol Cancer Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion.
Dominico Vigil, Tai Young Kim, Ana Plachco, Andrew J Garton, Linda Castaldo

Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.
Andrew J Garton, Linda Castaldo, Jonathan A Pachter

Methods Enzymol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
Kendall D Carey, Andrew J Garton, Maria S Romero, Jennifer Kahler, Stuart Thomson

Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.
Andrew J Garton, Andrew P A Crew, Maryland Franklin, Andrew R Cooke, Graham M Wynne

Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis